Police & Firemen s Retirement System of New Jersey Grows Holdings in Boston Scientific Corporation $BSX

Police & Firemen s Retirement System of New Jersey lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 4.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 224,434 shares of the medical equipment provider’s stock after acquiring an additional 10,325 shares during the quarter. Police & Firemen s Retirement System of New Jersey’s holdings in Boston Scientific were worth $24,106,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its position in shares of Boston Scientific by 2.0% during the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock worth $3,466,320,000 after buying an additional 622,602 shares during the period. PNC Financial Services Group Inc. raised its position in Boston Scientific by 5.5% in the 2nd quarter. PNC Financial Services Group Inc. now owns 1,215,796 shares of the medical equipment provider’s stock valued at $130,589,000 after purchasing an additional 63,237 shares in the last quarter. Comprehensive Financial Planning Inc. PA purchased a new position in shares of Boston Scientific in the 2nd quarter valued at about $180,000. Tobam grew its position in shares of Boston Scientific by 12.0% during the second quarter. Tobam now owns 1,334 shares of the medical equipment provider’s stock worth $143,000 after buying an additional 143 shares in the last quarter. Finally, KBC Group NV increased its stake in shares of Boston Scientific by 18.7% during the second quarter. KBC Group NV now owns 2,662,573 shares of the medical equipment provider’s stock worth $285,987,000 after buying an additional 419,460 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Up 1.6%

NYSE:BSX opened at $104.12 on Thursday. The company has a market capitalization of $154.34 billion, a PE ratio of 55.68, a P/E/G ratio of 2.02 and a beta of 0.58. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50. The stock’s 50 day moving average price is $99.85 and its 200 day moving average price is $102.54. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the prior year, the business earned $0.63 EPS. Boston Scientific’s quarterly revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. This trade represents a 21.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares in the company, valued at approximately $2,371,889.52. The trade was a 34.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 175,782 shares of company stock valued at $17,742,314. 0.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Leerink Partners lifted their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. BTIG Research restated a “buy” rating and issued a $132.00 price objective on shares of Boston Scientific in a report on Wednesday, October 22nd. Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and increased their target price for the company from $118.00 to $125.00 in a report on Monday, September 8th. Finally, Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 11th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $123.77.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.